Literature DB >> 31451952

On the Comparison of Methods in Analyzing Bounded Outcome Score Data.

Chuanpu Hu1.   

Abstract

Clinical trial endpoints often take the form of bounded outcome scores (BOS) which report a discrete set of values on a finite range. Conceptually such endpoints are ordered categorical in nature, but in practice they are often analyzed as continuous variables, which may result in data range violations and difficulties to handle data skewness. Analysis methods dedicated for BOS data have been proposed; however, much confusion exists among pharmacometricians on how to compare the possible methods. This commentary reviews the main methods used in pharmacometrics applications and discusses their theoretical and practical comparisons. The expected performance of some conceptually appealing methods in different situations is discussed, and a guideline is provided on selecting analysis methods in practice.

Keywords:  categorical data; likelihood; model selection; nonlinear mixed-effects modeling; transformation

Mesh:

Year:  2019        PMID: 31451952     DOI: 10.1208/s12248-019-0370-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  9 in total

1.  Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.

Authors:  Chuanpu Hu; Bruce Randazzo; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-20       Impact factor: 2.745

2.  The logistic transform for bounded outcome scores.

Authors:  Emmanuel Lesaffre; Dimitris Rizopoulos; Roula Tsonaka
Journal:  Biostatistics       Date:  2006-04-05       Impact factor: 5.899

3.  Estimating transformations for repeated measures modeling of continuous bounded outcome data.

Authors:  Matthew M Hutmacher; Jonathan L French; Sriram Krishnaswami; Sujatha Menon
Journal:  Stat Med       Date:  2011-01-13       Impact factor: 2.373

4.  Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.

Authors:  Chuanpu Hu; Omoniyi J Adedokun; Liping Zhang; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

5.  Modeling continuous response variables using ordinal regression.

Authors:  Qi Liu; Bryan E Shepherd; Chun Li; Frank E Harrell
Journal:  Stat Med       Date:  2017-09-05       Impact factor: 2.373

6.  Bounded outcome score modeling: application to treating psoriasis with ustekinumab.

Authors:  Chuanpu Hu; Newman Yeilding; Hugh M Davis; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-18       Impact factor: 2.745

7.  A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables.

Authors:  Michael Smithson; Jay Verkuilen
Journal:  Psychol Methods       Date:  2006-03

8.  A Bounded Integer Model for Rating and Composite Scale Data.

Authors:  Gustaf J Wellhagen; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

9.  Exposure-response modeling of clinical end points using latent variable indirect response models.

Authors:  C Hu
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-04
  9 in total
  2 in total

1.  Applying Beta Distribution in Analyzing Bounded Outcome Score Data.

Authors:  Chuanpu Hu; Honghui Zhou; Amarnath Sharma
Journal:  AAPS J       Date:  2020-03-17       Impact factor: 4.009

2.  Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Authors:  Yassine Kamal Lyauk; Daniël M Jonker; Andrew C Hooker; Trine Meldgaard Lund; Mats O Karlsson
Journal:  AAPS J       Date:  2021-02-25       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.